NCT00003440View on ClinicalTrials.gov

Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic

PHASE3CompletedINTERVENTIONAL

Enrollment

580

Participants

Timeline

Start Date

July 31, 1998

Primary Completion Date

July 31, 2004

Conditions

HER2-negative Breast CancerHER2-positive Breast CancerRecurrent Breast CancerStage IIIC Breast CancerStage IV Breast Cancer

Interventions

DRUG

paclitaxel

Given IV over 1 hour or 3 hours

BIOLOGICAL

trastuzumab

Given IV

PROCEDURE

quality-of-life assessment

Ancillary studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00003440 - Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | Biotech Hunter | Biotech Hunter